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Liver cancer incidence is increasing, with
782,000newcasesworldwide in2012,more
than 1 million cases per year projected
by 2025, and a ratio of mortality to inci-
dence close to unity, thereby suggesting
a poor prognosis.1 Hepatocellular carci-
noma (HCC) represents nearly 90% of all
primary liver cancers, and, typically, eti-
ologic factors vary greatly by geographic
regions around the globe. Indeed, a mul-
tifaceted portrait ofHCC is rapidly emerging
with several implications ahead, challenging
clinicians in terms of public healthmeasures
and treatment strategies.
Whereas a significant reduction of hep-
atitis C virus (HCV) infections in Japan and
hepatitis B virus infections in China have
brought a decline in HCC, HCV infection
rates in Oceania, Western Europe, and
NorthAmerica are steadily increasing.As a
result,HCC trends in suchhistorically low-
risk areas are increasing, and HCC is now
included among the more frequent causes
of cancer-related deaths. Meanwhile, in
Western countries, diabetes, obesity, and
related nonalcoholic fatty liver disease,
which are the hallmarks of the vast spec-
trumofmetabolic syndrome, becomemore
frequently recognized as risk factors for
HCC2 harboring distinctive clinical features
from virus-induced counterparts.3
Regardless of its goals, curative or
palliative, treatmentofHCCismainly stage
driven, with the Barcelona Clinic Liver
Cancer staging system being one of the
most comprehensive tools. Nonetheless,
other systems, suchas theHongKongLiver
Cancer system recently proposed, might
be more appropriate and perform better,
for example, in Asian populations where
hepatitis B virus infection is still the pre-
dominant risk factor for HCC. Still, treat-
ment recommendations also need to be
tailored according to resource availabil-
ity and to diverse health care systems
capabilities.4
Given these premises, in this issue of
Journal of Oncology Practice, Rich et al5
provide a succinct but inclusive review on
themanagement of HCC. In addition, they
report on treatment modalities that per-
haps are more peculiar to patterns of care
observed within health systems of high-
income countries, particularly the United
States. In fact, the promising role of ste-
reotactic body radiation therapy6 now
belongs to a context where current fig-
ures seem to have definitely outpaced the
guidelines of most professional societies.
This certainlymirrors an attitude sharedby
several institutions gauging risks and
benefits of treatment options for the in-
dividual patient on the basis of more
updated evidence, routinely discussed in
the frame ofmultidisciplinary hepatobiliary
tumor teams. Counterintuitive as they may
seem to be, even the preliminary findings
reported on early HCC recurrences after
direct-acting antivirals against hepatitis C7
reflect treatment strategies whose sustain-
ability, again, would be questioned in many
low-income countries. Clearly, for both
liver stereotactic body radiation therapy
and direct-acting antivirals, more robust
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data are much awaited before reaching firm conclusions on
their right place in the management of HCC.
When it comes to the advanced-disease setting, a point
perhaps not fully addressed by Rich et al5 relates to possi-
ble approaches that need to be developed to individualize
treatments, a relevant challenge in HCC. Evidence suggests
that, similar to other oncology fields, a one-size-fits-all
approach is not appropriate in HCC. Many data gained on
clinical grounds hint at optimizing sorafenib therapy (or
subsequent therapies), for instance, according to HCV
status,8 a-fetoprotein response9 and a-fetoprotein levels,
patterns of disease progression,10 or reasons for sorafenib
discontinuation.10 As a matter of fact, because nearly
30% of patients eligible for second-line treatments per-
manently discontinue sorafenib as a result of an adverse
event, a sound inclusion criterion of the Regorafenib
After Sorafenib in Patients with Hepatocellular Carcinoma
(RESORCE) study of regorafenib versus placebo was to
limit the enrollment only to those patients who could
tolerate sorafenib. From a clinician’s standpoint, this strict
criterion precludes any consideration about regorafenib
efficacy in patients who cannot tolerate sorafenib but,
not unexpectedly, it allows observation of a lower rate of
treatment-related adverse events in patients receiving
regorafenib.
Nevertheless, in managing patients with HCC, one of the
major hurdles remains HCC heterogeneity, not only at the
epidemiologic level but also at the molecular level. Because
HCC is the only cancer type where a diagnosis can be de-
terminedintheabsenceofhistologicconfirmation,onlyasmall
proportion of patients with atypical imaging will ultimately
undergo liver biopsy. However, the substantial lack of biologic
specimens from the majority of patients with HCC, including
those enrolled in most trials published thus far, has long
hampered biomarker discovery in this disease. In this re-
spect, although negative, the phase III METIV-HCC trial
(ClinicalTrials.gov identifier: NCT01755767), by requesting a
mandatory assessment of tumor mesenchymal-epithelial
transition factor, was the first biomarker-driven trial
and, hopefully, it has paved the way for a novel generation of
clinical trials in HCC with biomarker-based enrichment
strategies.
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